Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SIMLANDI - Health Canada Drug Approval Details

Approvals/Health Canada/SIMLANDI

Authorized

STANDARD

SIMLANDI

Jamp Pharma Corporation🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 58c915a8512f628e
Company: Jamp Pharma Corporation
Type: Standard

Approval Details

Approval Id: 58c915a8512f628e
Drug Approval Canada Name: SIMLANDI
Product Name: SIMLANDI
Status: Marketed
Status Date: 2022-04-13
Original Market Date: 2022-04-13
Din: 02523957
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 90:24.16.92
Atc Original: L04AB04 ADALIMUMAB
Atc Name: l 04 ab 04
Aig Number: 0150364002
Company Name: Jamp Pharma Corporation
Company Address: 1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Company Detail Path: /organization/jamp-pharma-corporation

Company Information

Pharmaceutical Company Name: Jamp Pharma Corporation
Country Name: Canada
Province Name: British Columbia
City Name: chilliwack,british columbia,country_ca
Address: 8065 Aitken Rd

Active Ingredients

ADALIMUMAB

40 MG / 0.4 ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

58c915a8512f628e

Type

Standard

Back to Health Canada Approvals